ReviewJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2015
Pharmacotherapy of glaucoma.
Review in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04676126 (Augmented Macular Pigment Supplement and Pericentral Visual Function), which is not on this map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Augmented Macular Pigment Supplement and Pericentral Visual Function: a Randomized Controlled Trial
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.
- Efficacy and safety of PreserFlo MicroShunt versus trabeculectomy in glaucoma patients: a systematic review, meta-analysis, and meta-regression of clinical outcomes and key covariates.BMC ophthalmology · 2026Pooled it
- Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022Trial
- Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.Advances in therapy · 2016Trial
- Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics.Advances in therapy · 2016Trial
- Effects of Ripasudil Hydrochloride Hydrate-Brimonidine Tartrate Fixed-Dose Combination Using Rho Kinase Inhibitor and Alpha2 Adrenergic Receptor Agonist on Aqueous Column in the Episcleral Vein: A Randomized, Double-Masked, Crossover Clinical Trial (ROCK Alpha-Aqua Study).Journal of clinical medicine · 2026Article
- Prostaglandin analog therapy challenges and innovation in glaucoma therapeutics.Indian journal of ophthalmology · 2026Review
- The Sigma-1 Receptor Agonist Fluvoxamine Is Protective in Hyperglycaemia-Induced Dysfunction of Trabecular Meshwork Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- NeuProIO: A dual-Action Solid Drug Nanoparticle Topical Formulation for Simultaneous Intraocular Pressure Reduction and Neuroprotection for Glaucoma.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2026Article
- Changes of Schlemm's Canal and Trabecular Meshwork Dimensions from Digital Ocular Massage in High Myopia: A Pilot Study.Ophthalmic research · 2026Article
- XEN‑45 implantation for refractory secondary glaucoma.BMC ophthalmology · 2025Article
- Changes in Ocular Biometry After Pharmacologic Cycloplegia and Mydriasis in Primary Angle Closure Disease.Ophthalmology and therapy · 2025Article
- Article
- Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model.Chinese medical journal · 2025Article
- A simple mathematical approach to identifying baseline predictors of the effectiveness of carbonic anhydrase inhibitors in intraocular pressure reduction.Digital journal of ophthalmology : DJO · 2025Article
- Short-term digital ocular massage may weaken corneal biomechanics.Frontiers in bioengineering and biotechnology · 2025Article
- The endocannabinoid system and ophthalmic pathologies: a review of molecular mechanisms and its implications for clinical practice.Frontiers in medicine · 2025Review
- Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management.Discover nano · 2024Review
- Near-infrared activated liposomes for neuroprotection in glaucoma.Journal of materials chemistry. B · 2024Article
- Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents.Drug delivery and translational research · 2024Article
- Dexamethasone Impairs ATP Production and Mitochondrial Performance in Human Trabecular Meshwork Cells.Current issues in molecular biology · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a group of diseases involving the optic nerve and associated structures, which is characterized by progressive visual field loss and typical changes of the optic nerve head (ONH). The only known treatment of the disease is reduction of intraocular pressure (IOP), which has been shown to reduce glaucoma progression in a variety of large-scale clinical trials. Nowadays, a relatively wide array of topical antiglaucoma drugs is available, including prostaglandin analogues, carbonic anhydrase inhibitors, beta-receptor antagonists, adrenergic agonists, and parasympathomimetics. In clinical routine, this allows for individualized treatment taking risk factors, efficacy, and safety into account. A major challenge is related to adherence to therapy. Sustained release devices may help minimize this problem but are not yet available for clinical routine use. Another hope arises from non-IOP-related treatment concepts. In recent years, much knowledge has been gained regarding the molecular mechanisms that underlie the disease process in glaucoma. This also strengthens the hope that glaucoma therapy beyond IOP lowering will become available. Implementing this concept with clinical trials remains, however, a challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.